Details:

Alternative Title:
Emerg Infect Dis
Personal Author:
Parashar, U. D.; Bresee, J. S.; Gentsch, J. R.; Glass, R. I.;
Parashar, U. D.; Bresee, J. S.; Gentsch, J. R.; Glass, R. I.; Less -
Description:
Rotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through vaccination. Serotypespecific immunity may play a role in protection from disease. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) (which contains a rhesus rotavirus with serotype G3 specificity and reassortant rhesus-human rotaviruses with G1, G2, and G4 specificity) provides coverage against the four common serotypes of human rotavirus. In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. This vaccine was licensed by the U.S. Food and Drug Administration on August 31, 1998, and should be cost-effective in reducing diarrheal diseases in industrialized countries. The vaccine's efficacy and cost-effectiveness in developing countries should be evaluated.
Subject:
[+]
Animals
Humans
Research Article
Rotavirus
Rotavirus Infections
Viral Vaccines

Source:
Emerg Infect Dis. 4(4):561-570.;
Document Type:
Journal Article;
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:9a51d5628ae73267724703afb8da32f5019cc6e432c9c2405d9e147d52a7a5b4
File Type:

Supporting Files

• 	9866732.nxml	txt
  	license.txt	txt

More +